Oragenics, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended June 30, 2015. The company develops antibiotics and live biotherapeutic products and sells oral-health probiotics. It reported as a smaller reporting company; its interim financial statements are unaudited.
Financial performance and position
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 |
|---|---|---|
| Revenue | $242,038 | $605,812 |
| Gross profit | $155,256 | $351,033 |
| Gross margin | 64.1% | 57.9% |
| Research and development | $5,611,921 | $6,288,516 |
| Selling, general and administrative | $873,630 | $1,689,095 |
| Net loss | $(6,335,471) | $(7,628,248) |
| Basic and diluted loss per share | $(0.17) | $(0.21) |
- For the six months, operating cash use was $2.23 million, investing cash use $93,889, and financing cash use $79,468. Cash and cash equivalents declined $2.41 million to $8.04 million.
- At June 30, total assets were $8.70 million, current assets $8.52 million, current liabilities $5.60 million, and shareholders’ equity $3.09 million. Working capital was $2.92 million, down from $10.23 million at December 31, 2014.
- Current liabilities included a $5.0 million unsecured convertible note to Intrexon, bearing 3% interest and due December 31, 2015. The company may repay in cash or common shares; share repayment requires shareholder approval. Short-term insurance-financing notes totaled $34,767.
- Accumulated deficit was $83.57 million. The company reported recurring losses and operating cash outflows and had not achieved profitability.
Changes versus comparable 2014 periods
- Second-quarter revenue decreased 20.3% to $242,038 from $303,752, primarily due to lower private-label sales. Six-month revenue increased 16.9% to $605,812 from $518,412, primarily due to international distributor sales.
- Second-quarter gross margin improved to 64.1% from 58.6%; six-month gross margin declined to 57.9% from 60.4%, with increased scrap expense contributing to higher cost of sales.
- Six-month R&D expense rose $4.37 million to $6.29 million, primarily reflecting the $5.0 million Oral Mucositis technology access fee recorded through the convertible note, partly offset by lower third-party research costs. The note-funded fee is also shown as a noncash adjustment in the cash flow statement.
- Six-month SG&A declined 13.1% to $1.69 million. Six-month net loss increased to $7.63 million from $3.54 million; operating cash use fell to $2.23 million from $3.28 million.
Outlook, programs, and material items
- Management said cash at June 30 was expected to support the business as then structured for about nine months, assuming the convertible note and accrued interest could be paid in shares. It separately stated existing cash could fund Lantibiotic ECC work and normal operating costs through March 2016, but additional capital would be needed to begin Oral Mucositis ECC work and support further development. These estimates are conditional, and no committed financing was available.
- Management expects substantial expenditures and losses for the foreseeable future. Funding may be sought through equity or debt, grants, sublicensing, partnerships, or other transactions; availability and terms are uncertain and equity financing could dilute shareholders.
- In July 2015, after the reporting period, the company announced positive results in a Syrian Golden Hamster C. difficile model and selected a lead lantibiotic candidate. It targeted an FDA pre-IND meeting in fourth-quarter 2015 and an IND filing for a first-in-human study in 2016; these are plans, not assured outcomes.
- The June 2015 Oral Mucositis ECC covers continued development of AG013 and other products. It entails a 12% net-sales royalty to Intrexon and substantial future milestone obligations, potentially payable in cash or shares. No milestones under the disclosed Intrexon collaborations had been achieved by June 30.
- The company had scaled back probiotic marketing, reported limited success and did not expect near-term significant sales growth. It was exploring strategic alternatives for that business. The patent licensed for SMaRT Replacement Therapy expired in June 2015; the company was evaluating its options.
- Texas A&M extended the first-patient Phase I milestone deadline to June 30, 2016. None of the Texas A&M milestones had been achieved as of June 30.
- On August 3, 2015, Griffin Securities exercised 185,585 previously issued warrants, resulting in issuance of 98,592 common shares. As of August 7, 36,477,536 common shares were outstanding.
- Management concluded disclosure controls were effective, but disclosed a continuing material weakness in internal control over financial reporting due to inadequate segregation of duties related to the company’s small staff. Management said additional procedures were used to support financial reporting.
Important facts for investors to verify
- Whether the $5.0 million Intrexon note, interest, and any required shareholder approval can be addressed by the December 31, 2015 maturity without materially reducing liquidity or diluting shareholders.
- Actual cash runway and financing requirements, including funding for Oral Mucositis development and the other collaboration programs.
- Progress toward the lantibiotic pre-IND meeting and IND filing, and whether animal-model results are reproduced in subsequent studies.
- Future probiotic sales, margins, and the outcome of the strategic-alternatives process.
- Potential dilution and payment obligations under Intrexon milestone and royalty arrangements, as well as the effects of concentrated ownership.
- Remediation of the internal-control material weakness and the status of the Texas A&M license milestone.